公开(公告)号：US08680048B2

公开(公告)日：2014-03-25

申请号：US13656012

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  A01N43/04 ,  A61K31/70

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20130102526A1

公开(公告)日：2013-04-25

申请号：US13656012

申请日：2012-10-19

Applicant: ABBVIE INC.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A61K38/07 ,  A61P31/14 ,  A61K31/7068 ,  A61K31/7072 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/501 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7072 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).